Role of Myeloid-Derived Suppressor Cells (MDSCs), Specifically Monocyte-Derived MDSCs, in Type 2 Diabetes-Related...

The role of myeloid-derived suppressor cells (MDSCs) in the pathogenesis of diabetic retinopathy (DR) in patients with type 2 diabetes remains unclear. Thus, we aimed to determine whether these cells are involved in the pathogenesis of DR.

Blood samples were collected from 42 patients with type 2 diabetes and DR and 20 age- and sex-matched healthy volunteers. MDSCs, including monocyte-derived (M-MDSCs) and granulocyte-derived (G-MDSCs) subpopulations, were detected via flow cytometry.

The difference in the percentage of peripheral blood M-MDSCs among the three groups was statistically significant. Significant differences were observed between proliferative DR (PDR), nonproliferative DR (NPDR), and healthy controls in terms of M-MDSC percentage. No significant differences were observed between the NPDR and healthy control groups. The percentage of peripheral blood G-MDSCs did not significantly differ among the three groups. Moreover, the proportion of M-MDSCs in the peripheral blood of patients positively correlated with fasting blood glucose and glycosylated hemoglobin levels.

The percentage of M-MDSCs in peripheral blood was significantly higher in the PDR group and positively correlated with fasting blood glucose and glycosylated hemoglobin levels. Our findings suggest that M-MDSCs, particularly in the proliferative stage of DR, may serve as potential biomarkers for disease progression and offer insights into future clinical or therapeutic strategies.